CD274 and non-small cell lung carcinoma: With respect to ICI immunotherapy, in the latest National Comprehensive Cancer Network (NCCN) guideline insights for NSCLC, the appropriate use of PD-1/PD-L1 inhibitors is determined by using levels of PD-L1 expression.